Current Performance and On-Going Improvements of the 8.2 m Subaru Telescope

An overview of the current status of the 8.2 m Subaru Telescope constructed and operated at Mauna Kea, Hawaii, by the National Astronomical Observatory of Japan is presented. The basic design concept and the verified performance of the telescope system are described. Also given are the status of the instrument package offered to the astronomical community, the status of operation, and some of the future plans. The status of the telescope reported in a number of SPIE papers as of the summer of 2002 are incorporated with some updates included as of 2004 February. However, readers are encouraged to check the most updated status of the telescope through the home page, http://subarutelescope.org/index.html, and/or the direct contact with the observatory staff.Comment: 18 pages (17 pages in published version), 29 figures (GIF format), This is the version before the galley proo

Factor of increased propofol dosage during dental treatment under intravenous anesthesia.

Introduction　Dental treatment using propofol (trade name Diprivan) was carried out for people with disabilities who have difficulties with dental treatment so that dental treatment could be carried out safely and smoothly. This time, we investigated for the purpose of clarifying the factors of those who need 3.5 µg/ml or more when sedated with propofol.　Object and method　Methods　　The subjects were 34 persons, who required the intravenous anesthesia method at the time of dental treatment, among patients who visited Matsumoto Dental University Hos-pital special specialist department from May 1st to September 30 th , 2015. Gender, age, presence or absence of regular medications were noted, weight and height were measured, and BMI was calculated. Disease, treatment, type of disability, and intellectual level from the　medical record were entered on the survey form. As an evaluation of adaptability to dental treatment, they were classified into 4 stages: “Can sit on the medical table”; “Can sleep the 　treatment table”; “Can do an oral examination”; and “Can do PTC”.　The diffuser TCI function was used to initiate intravenous administration at the target 　blood concentration of 3.0 µg/ml. Dental treatment was started with blood concentration in the brain when the opening device was smoothly inserted. If this target was not possible,　0.2 µg/ml each was listed. Blood concentrations and intracerebral concentrations of propofol during treatment were recorded. The intracerebral concentration where the opening device was smoothly inserted, the lowest brain concentration and the maximum brain concentration at the time of treatment were also recorded.Result　34 subjects (28 males, 6 females) had an average age of 37.6±12.4 years. The items asso-　ciated with brain concentration of propofol were subjects aged 50 years or older (P = 0.01), 　BMI (P = 0.15), dental phobia (P = 0.001), and autistic spectrum disease (P = 0.07). The factor that required propofol brain concentration of over 3.5 µg/ml was dental phobia (odds ratio: 28.5: confidence interval 1.₉–421) by the logistic regression analysis.　Conclusion　A factor that requires propofol of 3.5 µg/ml or more at the time of dental treatment, for those who can assume a supine position without making refusing actions at the medical table, was dental phobia. There was no relevance to the content of treatment or to the adaptability to dental treatment.

Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarteria Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma

IntroductionSeveral clinical trials comparing the efficacy and safety of transarterial chemoembolization (TACE) plus molecular-targeted agents versus TACE alone revealed no clinical benefits in progression-free survival (PFS) or overall survival (OS). Here, we report the final OS analysis from the TACTICS trial, which previously demonstrated significant improvement in PFS with TACE plus sorafenib in patients with unresectable hepatocellular carcinoma (HCC) (NCT01217034).MethodsPatients with unresectable HCC were randomized to a TACE plus sorafenib group (N = 80) or a TACE alone group (N = 76). Patients in the combination treatment group received sorafenib 400 mg once daily for 2-3 weeks before TACE, followed by 800 mg once daily during on-demand conventional TACE sessions until time to untreatable progression. In this trial, TACE-specific PFS was used. TACE-specific PFS is defined as the time from randomization to progressive disease (PD) or death from any cause, and PD was defined as untreatable progression, caused by the inability of a patient to further receive or benefit from TACE for reasons that include intrahepatic tumor progression (25% increase vs. baseline) according to response evaluation criteria in cancer of the liver, the detection of extrahepatic spread, vascular invasion, or transient deterioration of liver function to Child-Pugh C after TACE.ResultsAt the cut-off date of July 31, 2020, 131 OS events were observed. The median OS was 36.2 months with TACE plus sorafenib and 30.8 months with TACE alone (hazard ratio [HR] = 0.861; 95% confidence interval [CI], 0.607-1.223; p = 0.40, ΔOS, 5.4 months). The updated PFS was 22.8 months with TACE plus sorafenib and 13.5 months with TACE alone (HR = 0.661; 95% CI, 0.466-0.938; p = 0.02). Post-trial treatments with active procedures/agents were received by 47 (58.8%) patients in the TACE plus sorafenib group and 58 (76.3%) in the TACE alone group (p = 0.01). In post hoc analysis, PFS and OS benefit were shown in HCC patients with tumor burden beyond up-to-7 criteria.ConclusionsIn TACTICS trial, TACE plus sorafenib did not show significant OS benefit over TACE alone; however, clinical meaningful OS prolongation and significantly improved PFS was observed. Thus, the TACE plus sorafenib can be considered a choice of treatment in intermediate-stage HCC, especially in patients with high tumor burden. Trial Registration: NCT01217034

Formative Factors of Membranous Substances on Dorsum of Tongue, Teeth, Buccal Mucosa in Elderly Persons Requiring Nursing Care

要介護者の口腔粘膜にみられる付着物は，痰，痂皮，剥離上皮と呼ばれているが，上皮成分を主体とした付着物を剥離上皮膜と定義づけ，本研究にて，要介護高齢者の口腔内に形成された剥離上皮膜を部位別に形成要因を検討した。調査対象者は，入院中の患者のうち65 歳以上の要介護高齢者70 名であった（81.1±7.7 歳）。入院記録より年齢，疾患，常用薬，寝たきり度を調査し，意識レベル，発語の可否，介助磨きの頻度は担当看護師から聴取した。歯科医師が口腔内診査を行い，膜状物質の形成の有無，Gingival Index などを評価した。形成された膜状物質は，歯科医師がピンセットで採取した。粘膜保湿度（舌背部，舌下粘膜）は，粘膜湿潤度試験紙（キソウエット®）により10秒法で評価した。採取された膜状物質は，通法に従ってパラフィン切片を作製し，HE 染色とサイトケラチン1 による免疫染色で重層扁平上皮か否かについて確認し，重層扁平上皮由来の角質変性物が認められたものを剥離上皮膜と判断した。剥離上皮膜形成の有無を従属変数として，患者背景・口腔内の14 項目，疾患の15 項目，常用薬の32項目，合計61項目を独立変数として部位ごとで決定木分析を行った。すべての部位で剥離上皮膜の形成に最優先される要因は「摂食状況」であり，経口摂取者には，剥離上皮膜がみられなかった。第2 位は舌背部で舌背湿潤度，頰部で開口，歯面の第3 位が開口であり，口腔粘膜の乾燥を示唆する結果であった。以上，剥離上皮膜の形成要因には口腔乾燥があり，保湿の維持が剥離上皮膜の予防につながると考えられた

Integrative Annotation of 21,037 Human Genes Validated by Full-Length cDNA Clones

The human genome sequence defines our inherent biological potential; the realization of the biology encoded therein requires knowledge of the function of each gene. Currently, our knowledge in this area is still limited. Several lines of investigation have been used to elucidate the structure and function of the genes in the human genome. Even so, gene prediction remains a difficult task, as the varieties of transcripts of a gene may vary to a great extent. We thus performed an exhaustive integrative characterization of 41,118 full-length cDNAs that capture the gene transcripts as complete functional cassettes, providing an unequivocal report of structural and functional diversity at the gene level. Our international collaboration has validated 21,037 human gene candidates by analysis of high-quality full-length cDNA clones through curation using unified criteria. This led to the identification of 5,155 new gene candidates. It also manifested the most reliable way to control the quality of the cDNA clones. We have developed a human gene database, called the H-Invitational Database (H-InvDB; http://www.h-invitational.jp/). It provides the following: integrative annotation of human genes, description of gene structures, details of novel alternative splicing isoforms, non-protein-coding RNAs, functional domains, subcellular localizations, metabolic pathways, predictions of protein three-dimensional structure, mapping of known single nucleotide polymorphisms (SNPs), identification of polymorphic microsatellite repeats within human genes, and comparative results with mouse full-length cDNAs. The H-InvDB analysis has shown that up to 4% of the human genome sequence (National Center for Biotechnology Information build 34 assembly) may contain misassembled or missing regions. We found that 6.5% of the human gene candidates (1,377 loci) did not have a good protein-coding open reading frame, of which 296 loci are strong candidates for non-protein-coding RNA genes. In addition, among 72,027 uniquely mapped SNPs and insertions/deletions localized within human genes, 13,215 nonsynonymous SNPs, 315 nonsense SNPs, and 452 indels occurred in coding regions. Together with 25 polymorphic microsatellite repeats present in coding regions, they may alter protein structure, causing phenotypic effects or resulting in disease. The H-InvDB platform represents a substantial contribution to resources needed for the exploration of human biology and pathology

Integrative annotation of 21,037 human genes validated by full-length cDNA clones.

publication en ligne. Article dans revue scientifique avec comité de lecture. nationale.National audienceThe human genome sequence defines our inherent biological potential; the realization of the biology encoded therein requires knowledge of the function of each gene. Currently, our knowledge in this area is still limited. Several lines of investigation have been used to elucidate the structure and function of the genes in the human genome. Even so, gene prediction remains a difficult task, as the varieties of transcripts of a gene may vary to a great extent. We thus performed an exhaustive integrative characterization of 41,118 full-length cDNAs that capture the gene transcripts as complete functional cassettes, providing an unequivocal report of structural and functional diversity at the gene level. Our international collaboration has validated 21,037 human gene candidates by analysis of high-quality full-length cDNA clones through curation using unified criteria. This led to the identification of 5,155 new gene candidates. It also manifested the most reliable way to control the quality of the cDNA clones. We have developed a human gene database, called the H-Invitational Database (H-InvDB; http://www.h-invitational.jp/). It provides the following: integrative annotation of human genes, description of gene structures, details of novel alternative splicing isoforms, non-protein-coding RNAs, functional domains, subcellular localizations, metabolic pathways, predictions of protein three-dimensional structure, mapping of known single nucleotide polymorphisms (SNPs), identification of polymorphic microsatellite repeats within human genes, and comparative results with mouse full-length cDNAs. The H-InvDB analysis has shown that up to 4% of the human genome sequence (National Center for Biotechnology Information build 34 assembly) may contain misassembled or missing regions. We found that 6.5% of the human gene candidates (1,377 loci) did not have a good protein-coding open reading frame, of which 296 loci are strong candidates for non-protein-coding RNA genes. In addition, among 72,027 uniquely mapped SNPs and insertions/deletions localized within human genes, 13,215 nonsynonymous SNPs, 315 nonsense SNPs, and 452 indels occurred in coding regions. Together with 25 polymorphic microsatellite repeats present in coding regions, they may alter protein structure, causing phenotypic effects or resulting in disease. The H-InvDB platform represents a substantial contribution to resources needed for the exploration of human biology and pathology

金属水酸化物の構造制御を基盤とした高機能固体触媒の開発に関する研究

University of Tokyo (東京大学